Analysis by Mount Sinai researcher from First-of-its kind global trial could lead to future therapies to prevent deadly ...

Most of these new drugs work by silencing the instructions from the LPA gene so a protein that is a key part of Lp(a) cholesterol isn’t produced. Muvalaplin works differently. It interferes ...

Among patients with stable chest pain and suspected CAD, elevated levels of lipoprotein(a) seem to indicate a greater likelihood of finding coronary stenosis on coronary computed tomography ...

Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it. Now, an alliance between Novartis and genetic testing specialist 23andMe is ...

LPA, a gene associated with lipoprotein(a), emerged as a novel risk factor for AMD. This is the first study to link LPA to AMD, suggesting a role in drusen formation. Reliance on retrospective ...

Genetic factors heavily influence Lp(a) levels, mainly through the LPA gene. Variations in this gene can lead to higher Lp(a) ...

Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment ...

Two therapeutic approaches to Lp(a) lowering are currently under investigation. Injectable RNA-based therapies that prevent translation of LPA messenger RNA may block the production of ApoA used ...

Novartis has turned to Ionis for another cardiovascular disease drug, putting $60 million down for a follow-up to lipoprotein(a)-targeting drug pelacarsen, which is now in phase 3 testing.

VERVE-301 uses a novel, in vivo gene editing approach designed to permanently turn off the LPA gene in the liver to reduce blood lipoprotein(a) [Lp(a)] levels. Lp(a) is a genetically validated ...